New drug for fatty liver disease first tested in healthy volunteers
NCT ID NCT06716905
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of a new drug called ACT500 in 72 healthy Chinese adults. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug moved through the body. The goal was not to treat disease but to gather essential safety data before testing in patients with non-alcoholic steatohepatitis (NASH).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Blood test and AI could spot liver cancer early, saving lives
- Painless liver check: could a quick scan replace the needle?
- Computer nudge boosts liver referrals
- Healthy volunteers needed to test safety of experimental NASH drug
- Can genes predict liver cancer? new study seeks answers